News

Number of news items returned: 201 to 220 records of 411

2016 So Far, Not So Good

29 January 2016

(13709 views)

"... Whilst 2015 may have finished with a Santa rally in capital markets, 2016 has started horribly with losses across the ...

Gartner lists Opmantek in 2016 Market Guide for Network Automation

27 January 2016

(14374 views)

"Opmantek (ASSOB:OMK) a multi award winning provider of IT infrastructure management and Audit solutions, today announced that it has been ...

Australian Trading & Investment Corporation Ltd – Update

21 January 2016

(13532 views)

"To all interested parties, welcome to an exciting 2016! ...Since our last update we’re finding tremendous traction in setting the foundation ...

Equity Crowdfunding and Investment Opportunties

29 December 2015

(13963 views)

Looking to assist investors and private businesses in 2016 - from the team at Funding Strategies.   Funding Strategies provides Corporate ...

2015: An Inflection Point?

16 December 2015

(13485 views)

"As 2015 draws to a close the year we thought we’d recap the year and look at what’s on the ...

CRe8 Home & Finance Ltd – last chance to participate in this innovative company

14 December 2015

(13483 views)

"...CRe8 has had a stellar 2015, the highlights of which are listed below; Glenvill Homes (CRe8’s home builder partner) committed to ...

Opmantek Sales growth a new record

14 December 2015

(13233 views)

"Opmantek (ASSOB:OMK) has continued on its high growth trajectory signing significant customer agreements in November throughout the USA and Latin ...

Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project, Rovina Project Shows Off Digital Reconstruction of the ARIS Priscilla Catacombs

08 December 2015

(13748 views)

"Ocular Robotics RE05 3D Scanner to be used in European Space Agency Moon Exploration Project.   Aerospace company GMV have been awarded ...

Australian Trading and Investment Corporation Investor Update

07 December 2015

(13314 views)

"To all interested parties, Since our last update there have been some exciting updates, as listed below:   ..Our model portfolio increased by ...

BioCube Corporation: A Promising Year End for BioCube

04 December 2015

(13803 views)

"This has been a busy and exciting few weeks for the team at BioCube Corporation. Commencing with an Austrade mission ...

BioCube Raising $3 Million

13 November 2015

(13710 views)

The Eco Investor website published the following article about BioCube on November 13th, 2015:   "The developer of a portable and community-sized ...

Funding Strategies Connect - November 2015

12 November 2015

(13173 views)

Dear Readers, Today it is my pleasure to introduce you to BioCube, Appee and China Dairy. Ocular Robotics and Opmantek have both ...

Pre-Christmas Networking Event Invitation

11 November 2015

(12374 views)

We are delighted to invite you  to a pre-Christmas networking event over drinks and canapes with the Funding Strategies &  ...

CRe8 Home & Finance: Close of offer – 18th December 2015

10 November 2015

(13215 views)

To Whom It May Concern: CRe8 has received a positive response from its offer with the following highlights:   Round 1 closed within ...

SEC Adopts Rules to Permit Crowdfunding

01 November 2015

(13049 views)

SEC Adopts Rules to Permit Crowdfunding - big news in the discussion around equity funding for emerging and growing companies! ...

Ocular Robotics Recognised as a Game Changer in Silicon Valley, and Media Interest in the Unique Capabilities of OCR’s 3D Scanners Grows with Articles from SPAR Point Group and Lidar News

26 October 2015

(12516 views)

"Ocular Robotics Recognised as a Game Changer in Silicon Valley. Ocular Robotics has been recognised as a game changer in the ...

Australian Trading and Investment Corporation update: New Team, New Home & Bigger Plans!

23 October 2015

(14446 views)

"Successfully launches a limited Convertible Note offering US Fund Manager and Australian Small Cap Equity Fund Manager join the Management Board The ...

Queensland Premier names Opmantek as Queensland's Leading ICT Exporter and Innovator

23 October 2015

(14378 views)

"Opmantek (ASSOB:OMK) has been acknowledged by Queensland Premier Annastacia Palaszczuk for innovation, leadership and for being QLD’s leading ICT exporter ...

Ocular Robotics Issues Supplementary Offer Document

19 October 2015

(13067 views)

"The Company has issued a Supplementary Offer Document, dated 17th October 2015 in order to provide investors with an update ...

CRe8 Home & Finance: Cornerstone $1m Investor and Trading Halt Update

15 October 2015

(13313 views)

"To Whom It May Concern: We are very pleased and excited to announce that CRe8 Home and Finance Ltd (CRe8) has ...

JNCI publication involving CytImmune's CYT-21625

10 March 18

 

"JNCI publication involving CytImmune's CYT-21625"

 

"Please find attached [via the link below] an article published in the most recent version of the Journal of the National Cancer Institute (JNCI). This publication reports on a series of animal experiments comparing CytImmune's second generation nanomedicine, CYT-21625, against the commonly used chemotherapy, paclitaxel.


Key points:

1) CYT-21625 was safe with no toxicities observed.
2) The study involved three cancer models:
• Two thyroid cancers, traditional mouse xenograft models
• One Pancreatic neuroendocrine cancer, a genetically engineered mouse model.
3) Both anaplastic thyroid cancer (ATC) and pancreatic neuroendorine cancer (PNETs) are rare/orphan diseases, and have abysmal 5 year survival rates -- less than 5% for ATC and 16% for PNET patients with advanced disease.
4) CYT-21625 out-performed paclitaxel as measured by overall survival and using biological indicators that were specific to each cancer and model used.
We believe this study confirms the potential of the the Aurimune platform to deliver existing cancer drugs more effectively and with fewer toxic side effects. The paper concludes:

"CYT-21625 is effective in mice with PNETs [Pancreatic NeuroEndocrine Tumors] and metastatic human thyroid cancer with no toxicities. Thus, CYT-21625 should be studied in patients with advanced PNETs and thyroid cancer."

*Note that this study also used a CYT-6091 monotherapy as a control. As expected in this setting, while CYT-6091 showed some limited efficacy, it was inferior to therapies in which TNF is delivered in combination with chemotherapy. "

 

David Oarr, Chief Communications Officer, Project Karkinos, 10 March 2018.

Additional Documents

JNCI_CYT21625